Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study is a retrospective chart review to assess the tolerability and efficacy of treatment with Simbrinzaâ„¢ used for patients with Open-Angle Glaucoma or Ocular Hypertension.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Simbrinzaâ„¢ | Patients treated with Simbrinzaâ„¢ (brinzolamide 1%/brimonidine 0.2%) as standard of care in clinical practice. No study drug is administered in this study. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| No Intervention | Other | No study drug is administered in this study. |
|
| Measure | Description | Time Frame |
|---|---|---|
| The time to first glaucoma therapy escalation occurrence or discontinuation of Simbrinza® | 2 Years |
| Measure | Description | Time Frame |
|---|---|---|
| The time to first glaucoma therapy escalation occurrence | 2 Years | |
| The time(s) to additional glaucoma therapy escalation occurrence(s) | 2 Years | |
| Specific AEs and SAEs occurring with a frequency of ≥5% |
Not provided
Inclusion Criteria:
Exclusion criteria:
Not provided
Not provided
Not provided
Patients with Open-Angle Glaucoma or Ocular Hypertension treated in clinical practice.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Medical Director | Allergan | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Wheaton | Illinois | United States |
Not provided
| ID | Term |
|---|---|
| D005902 | Glaucoma, Open-Angle |
| D009798 | Ocular Hypertension |
| ID | Term |
|---|---|
| D005901 | Glaucoma |
| D005128 | Eye Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
| 2 Years |